These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 12575618)

  • 21. [Correlation, in previously treated HIV-1 positive patients, between hypersensitivity reaction to abacavir and the presence of the HLA-B*5701 allele].
    Pérez Prior N; Rocher Milla A; Soler Company E; Flores Cid J; Sarria Chust B
    Farm Hosp; 2009; 33(3):155-60. PubMed ID: 19712599
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Abacavir and lamivudine combination.
    Somboonwit C; Kurtyka D; Velez AP
    Expert Opin Drug Metab Toxicol; 2009 Dec; 5(12):1599-606. PubMed ID: 19929448
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Switch from a first virologically effective protease inhibitor-containing regimen to a regimen containing efavirenz, nevirapine or abacavir.
    Abgrall S; Yeni PG; Bouchaud O; Costagliola D;
    AIDS; 2006 Oct; 20(16):2099-106. PubMed ID: 17053356
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Protease Inhibitor Transfer Study (PROTRA 1): abacavir and efavirenz in combination as a substitute for a protease inhibitor in heavily pretreated HIV-1-infected patients with undetectable plasma viral load.
    Bickel M; Rickerts V; Stephan C; Jacobi V; Rottmann C; Dauer B; Carlebach A; Thalhammer A; Miller V; Staszweski S
    HIV Med; 2005 May; 6(3):179-84. PubMed ID: 15876284
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Abacavir and lamivudine for the treatment of human immunodeficiency virus.
    Rizzardini G; Zucchi P
    Expert Opin Pharmacother; 2011 Sep; 12(13):2129-38. PubMed ID: 21787242
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adherence, side effects and efficacy of stavudine plus lamivudine plus nelfinavir in treatment-experienced HIV-infected patients.
    Roca B; Gómez CJ; Arnedo A
    J Infect; 2000 Jul; 41(1):50-4. PubMed ID: 10942640
    [TBL] [Abstract][Full Text] [Related]  

  • 27. New expanded access drugs for use in combination therapy.
    Notes Undergr; 1998; (No 37):suppl 1-2. PubMed ID: 11365823
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Are nelfinavir-containing regimens effective as second-line triple therapy?
    Bernasconi E; Magenta L; Piffaretti JC; Carota A; Moccetti T
    AIDS; 2000 Jan; 14(1):95-6. PubMed ID: 10714576
    [No Abstract]   [Full Text] [Related]  

  • 29. Fifth Conference on Retroviruses & Opportunistic Infections. Interview by Ron Baker.
    Follansbee S; Deeks S; Bartnoff H
    Newsline People AIDS Coalit N Y; 1998 Mar; ():7-14. PubMed ID: 11367453
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antiretroviral chemotherapy.
    Saag MS; Schooley RT
    Curr Clin Top Infect Dis; 1998; 18():154-79. PubMed ID: 9779354
    [No Abstract]   [Full Text] [Related]  

  • 31. Prospective HLA-B*5701 screening and abacavir hypersensitivity: a single centre experience.
    Waters LJ; Mandalia S; Gazzard B; Nelson M
    AIDS; 2007 Nov; 21(18):2533-4. PubMed ID: 18025891
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative biological and clinical outcomes after a switch from a virologically unsuccessful first protease inhibitor-containing antiretroviral combination to a 3-drug regimen containing efavirenz, nevirapine, or abacavir.
    Abgrall S; Yeni PG; Bouchaud O; Costagliola D;
    Clin Infect Dis; 2007 Jan; 44(1):120-7. PubMed ID: 17143827
    [TBL] [Abstract][Full Text] [Related]  

  • 33. High plasma levels of nelfinavir and efavirenz in two HIV-positive patients with hepatic disease.
    Maserati R; Villani P; Seminari E; Pan A; Lo Caputo S; Regazzi MB
    AIDS; 1999 May; 13(7):870-1. PubMed ID: 10357395
    [No Abstract]   [Full Text] [Related]  

  • 34. Incidence of abacavir hypersensitivity reactions in euroSIDA.
    Bannister WP; Friis-Møller N; Mocroft A; Viard JP; van Lunzen J; Kirk O; Gargalianos P; Bánhegyi D; Chiesi A; Lundgren JD;
    Antivir Ther; 2008; 13(5):687-96. PubMed ID: 18771052
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Four new antiretroviral medications will soon offer more options to HIV patients.
    Murphy MJ
    Fac Notes (New Orleans La); 1998; 10(4):1-3. PubMed ID: 11365545
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [HIV infection: DuPont Pharma presents the results of its antiretroviral agent].
    Allerg Immunol (Paris); 1998 Apr; 30(4):123-4. PubMed ID: 9631694
    [No Abstract]   [Full Text] [Related]  

  • 37. Incidence of resistance in a double-blind study comparing lopinavir/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine.
    Kempf DJ; King MS; Bernstein B; Cernohous P; Bauer E; Moseley J; Gu K; Hsu A; Brun S; Sun E
    J Infect Dis; 2004 Jan; 189(1):51-60. PubMed ID: 14702153
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Abacavir rechallenge has to be avoided in case of hypersensitivity reaction.
    Escaut L; Liotier JY; Albengres E; Cheminot N; Vittecoq D
    AIDS; 1999 Jul; 13(11):1419-20. PubMed ID: 10449301
    [No Abstract]   [Full Text] [Related]  

  • 39. Abacavir.
    Foster RH; Faulds D
    Drugs; 1998 May; 55(5):729-36; discussion 737-8. PubMed ID: 9585869
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Triple nucleoside reverse transcriptase inhibitor- vs. nonnucleoside reverse transcriptase inhibitor-containing regimens as first-line therapy: efficacy and durability in a prospective cohort of French HIV-infected patients.
    Cuzin L; Pugliese P; Bugnon F; Delpierre C; Cua E; Billaud E; Massip P; Raffi F; Dellamonica P
    HIV Med; 2005 Nov; 6(6):388-95. PubMed ID: 16268820
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.